ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical responses to these targeted therapies can be profound, with high rates of response and near-complete initial remissions, as exemplified by the BCR-Abl inhibitor imatinib in CML [17] and the BRAF inhibitor vemurafenib in melanoma [18].